Rising rates of cancer in young people: nature or nurture?
High-quality studies employing molecular pathological epidemiology frameworks could help pinpoint aetiologic mechanisms and help tackle a potential future epidemic among the youngest
Pioneering the future of immunotherapy: new targets, novel strategies
Several studies report on promising data with immunomodulation and alternative approaches
Early-stage immunotherapy significantly prolongs overall survival in triple-negative breast cancer
Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial
Pre-operative immunoradiation shows clinical benefit in patients with high-risk, early-stage breast cancer
Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy
Early-phase studies show therapeutic potential of oncolytic viruses across cancer types
However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses
Intravesical system for prolonged delivery of gemcitabine improves outcomes in two forms of bladder cancer
Findings from two studies show high rates of complete remissions in patients with Bacillus Calmette-Guérin unresponsive high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer
Clinical activity reported for novel first-line combination strategies in advanced triple-negative breast cancer
Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade
Adding durvalumab to neoadjuvant chemotherapy improves survival in muscle-invasive bladder cancer
Practice changing results of event-free survival and overall survival are reported from the NIAGARA study
Multi-cancer early detection – promise or reality?
While there has been significant progress in the development of these blood tests, hurdles remain including test sensitivity and false positives
Radiopharmaceuticals boost the efficacy of androgen-receptor pathway inhibitors in metastatic castration-resistant prostate cancer
The first results from two phase III studies of Ra-223 and 177Lu-PNT2002 may help to decipher their role in the treatment of patients with mCRPC